Decision-making tools to assist prognosis and treatment choices in early breast cancer: A review

Expert Review of Anticancer Therapy

Volumn 12, Issue 8, 2012, Pages 1033-1043

  Al Allak, Asmaa ^a   Lewis, Paul D ^b   Bertelli, Gianfilippo ^a  

^a SINGLETON HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Adjuvant! Online; breast cancer; MammaPrint; Nottingham Prognostic Index; Oncotype DX; PAM50; PREDICT; St Gallen Consensus Conference; TNM

Indexed keywords

ASSAY; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; COMPUTER PROGRAM; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; HUMAN; MOLECULAR BASED DECISION TOOL; MOLECULAR DIAGNOSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOTTINGHAM PROGNOSTIC INDEX; ONLINE ANALYSIS; ONLINE SYSTEM; REVIEW;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; GENETIC TESTING; GUIDELINES AS TOPIC; HUMANS; INTERNET; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84867068550     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.83     Document Type: Review

References (80)

1. Hèry C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann. Oncol. 19(6), 1187-1194 (2008).
2. Autier P, Boniol M, La Vecchia C et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 341, c3620 (2010).
3. Tabár L, Fagerberg CJ, Gad A et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1(8433), 829-832 (1985).
4. UK Trial of Early Detection of Breast Cancer Group. First results on mortality reduction in the UK Trial of early detection of breast cancer. Lancet 2(8608), 411-416 (1988).
5. Bjurstam N, Björneld L, Duffy SW et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 80(11), 2091-2099 (1997).
6. Lacroix M. A Concise History of Breast Cancer (Cancer Etiology, Diagnosis and Treatments: Women's Issues). Nova Science Publishers Inc, NY, USA 166 (2011).
7. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr. Rev. 30(4), 343-375 (2009).
8. Thürlimann B, Keshaviah A, Coates AS et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353(26), 2747-2757 (2005).
9. Howell A, Cuzick J, Baum M et al.; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
10. Coombes RC, Hall E, Gibson LJ et al.; Intergroup Exemestane Study. A randomized trial of exemestane after 2-3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350(11), 1081-1092 (2004).
11. Perez EA, Suman VJ, Davidson NE et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 29(34), 4491-4497 (2011).
12. Coleman RE, Marshall H, Cameron D et al.; AZURE Investigators. Breast cancer adjuvant therapy with zoledronic acid. N. Engl. J. Med. 365(15), 1396-1405 (2011).
13. Slamon D, Eiermann W, Robert N et al.; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273-1283 (2011).
14. Bedognetti D, Sertoli MR, Pronzato P et al. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized Phase III trial. J. Natl Cancer Inst. 103(20), 1529-1539 (2011).
15. Eiermann W, Pienkowski T, Crown J et al. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J. Clin. Oncol. 29(29), 3877-3884 (2011).
16. Pritchard KI, Shepherd LE, Chapman JA et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J. Clin. Oncol. 29(29), 3869-3876 (2011).
17. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J. Clin. Oncol. 29(25), 3366-3373 (2011).
18. Coombes RC, Bliss JM, Espie M et al. Randomized, Phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer. J. Clin. Oncol. 29(24), 3247-3254 (2011).
19. Gnant M, Mlineritsch B, Stoeger H et al.; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12(7), 631-641 (2011).
20. Spigel DR, Hainsworth JD, Burris HA 3rd et al. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. Clin. Adv. Hematol. Oncol. 9(4), 280-286 (2011).
21. Albert JM, Buzdar AU, Guzman R et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res. Treat. 128(2), 421-427 (2011).
22. Gianni L, Dafni U, Gelber RD et al.; Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12(3), 236-244 (2011).
23. McArthur HL, Rugo H, Nulsen B et al. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albuminbound paclitaxel in early-stage breast cancer. Clin. Cancer Res. 17(10), 3398-3407 (2011).
24. Karlsson P, Sun Z, Braun D et al. Longterm results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann. Oncol. 22(10), 2216-2226 (2011).
25. Aebi S, Sun Z, Braun D et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow-up on IBCSG Trial IX. Ann. Oncol. 22(9), 1981-1987 (2011).
26. van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised Phase 3 trial. Lancet 377(9762), 321-331 (2011).
27. Margolin S, Bengtsson NO, Carlsson L et al.; Scandinavian Breast Group Study SBG 2004-1. A randomised feasibility/Phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophosphamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. Acta Oncol. 50(1), 35-41 (2011).
28. Benson JR, Weaver DL, Mittra I, Hayashi M. The TNM staging system and breast cancer. Lancet Oncol. 4(1), 56-60 (2003).
29. Blamey RW, Davies CJ, Elston CW, Johnson J, Haybittle JL, Maynard PV. Prognostic factors in breast cancer-the formation of a prognostic index. Clin. Oncol. 5(3), 227-236 (1979).
30. Haybittle JL, Blamey RW, Elston CW et al. A prognostic index in primary breast cancer. Br. J. Cancer 45(3), 361-366 (1982).
31. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat. 22(3), 207-219 (1992).
32. Blamey RW, Ellis IO, Pinder SE et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur. J. Cancer 43(10), 1548-1555 (2007).
33. Blamey RW, Mitchell MJ, Ball GR et al. O-91 Prognostic estimation: re-analysis of data from cases diagnosed in 1990-1999 by Cox proportional hazards method. Eur. J. of Cancer Suppl. 5(3), 28 (2007).
34. Albergaria A, Ricardo S, Milanezi F et al. Nottingham Prognostic Index in triplenegative breast cancer: a reliable prognostic tool?. BMC Cancer 11, 299 (2011).
35. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19(4), 980-991 (2001).
36. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352(9132), 930-942 (1998).
37. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114), 1451-1467 (1998).
38. Agarwal V, O'Neill P. UK national survey on the use of adjuvantonline as a decisionmaking tool in early breast cancer. Eur. J. Cancer Suppl. 7(2), 318 (2009).
39. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J. Clin. Oncol. 23(12), 2716-2725 (2005).
40. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J. Clin. Oncol. 27(2), 214-219 (2009).
41. Paridaens RJ, Gelber S, Cole BF et al. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogenreceptor-positive breast cancer. Breast Cancer Res. Treat. 123(1), 303-310 (2010).
42. Mook S, Schmidt MK, Rutgers EJ et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospitalbased retrospective cohort study. Lancet Oncol. 10(11), 1070-1076 (2009).
43. Bhoo-Pathy N, Yip CH, Hartman M et al. Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur. J. Cancer 48(7), 982-989 (2012).
44. Wishart GC, Azzato EM, Greenberg DC et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 12(1), R1 (2010).
45. Wishart GC, Bajdik CD, Azzato EM et al. A population-based validation of the prognostic model PREDICT for early breast cancer. Eur. J. Surg. Oncol. 37(5), 411-417 (2011).
46. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifentreated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
47. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
48. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer 7(4), 347-350 (2006).
49. Albain KS, Barlow WE, Shak S et al.; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11(1), 55-65 (2010).
50. Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
51. Cronin M, Sangli C, Liu ML et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogenreceptor-positive breast cancer. Clin. Chem. 53(6), 1084-1091 (2007).
52. Asad J, Jacobson AF, Estabrook A et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am. J. Surg. 196(4), 527-529 (2008).
53. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW. The influence of a gene expression profile on breast cancer decisions. J. Surg. Oncol. 99(6), 319-323 (2009).
54. Albanell J, González A, Ruiz-Borrego M et al. Prospective trans-GEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann. Oncol. 23(3), 625-631 (2012).
55. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4), 381-387 (2010).
56. Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic testdirected chemotherapy for early-stage lymph node-positive breast cancer. J. Natl Cancer Inst. 104(1), 56-66 (2012).
57. Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX recurrence score. Mod. Pathol. 21(10), 1255-1261 (2008).
58. Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?. Arch. Pathol. Lab. Med. 134(11), 1697-1701 (2010).
59. Williams DJ, Cohen C, Darrow M, Page AJ, Chastain B, Adams AL. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl. Immunohistochem. Mol. Morphol. 19(5), 431-436 (2011).
60. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11(2), 174-183 (2010).
61. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17(4), 323-334 (2008).
62. Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 29(32), 4273-4278 (2011).
63. Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER-positive patients: who does not always need testing?. Breast Cancer Res. Treat. 131(2), 413-424 (2012).
64. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
65. Bueno-de-Mesquita JM, Sonke GS, van de Vijver MJ, Linn SC. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Ann. Oncol. 22(9), 2021-2030 (2011).
66. Buyse M, Loi S, van't Veer L et al.; TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183-1192 (2006).
67. Rutgers E, Piccart-Gebhart MJ, Bogaerts J et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur. J. Cancer 47(18), 2742-2749 (2011).
68. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98(4), 262-272 (2006).
69. Reyal F, Bollet MA, Caly M et al. Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma. PLoS ONE 7(4), e35184 (2012).
70. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
71. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27(8), 1160-1167 (2009).
72. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin. Cancer Res. 16(21), 5222-5232 (2010).
73. Kelly CM, Bernard PS, Krishnamurthy S et al. Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX) and the PAM50 breast cancer intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. Oncologist 17(4), 492-498 (2012).
74. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22(8), 1736-1747 (2011).
75. Campbell HE, Taylor MA, Harris AL, Gray AM. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br. J. Cancer 101(7), 1074-1084 (2009).
76. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 28(9), 963-968 (2010).
77. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 109(9), 1721-1728 (2007).
78. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8(3), 235-244 (2007).
79. Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel) 6(2), 136-141 (2011).
80. Curtis C, Shah SP, Chin SF et al.; METABRIC Group; Co-chairs; Writing committee; Steering committee; Tissue and clinical data source sites:; University of Cambridge/Cancer Research UK Cambridge Research Institute; British Columbia Cancer Agency; University of Nottingham; King's College London; Manitoba Institute of Cell Biology; Cancer genome/transcriptome characterization centres:; University of Cambridge/Cancer Research UK Cambridge Research Institute; British Columbia Cancer Agency; Data analysis subgroup:; Universityof Cambridge/Cancer Research UK Cambridge Research Institute; British Columbia Cancer Agency. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature doi:10.1038/nature10983 (2012) (Epub ahead of print).